Menu Search
Equities

Guerbet SA

GBT:PAR

Guerbet SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)26.25
  • Today's Change-0.05 / -0.19%
  • Shares traded7.41k
  • 1 Year change+45.83%
  • Beta0.7504
Data delayed at least 15 minutes, as of Nov 22 2024 10:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy3
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in EUR

The 4 analysts offering 12 month price targets for Guerbet SA have a median target of 42.50, with a high estimate of 44.00 and a low estimate of 41.00. The median estimate represents a 61.60% increase from the last price of 26.30.
High67.3%44.00
Med61.6%42.50
Low55.9%41.00

Dividends

In 2023, Guerbet SA reported a dividend of 0.50 EUR, equaling last years dividend. The 3 analysts covering the company expect dividends of 0.52 EUR for the upcoming fiscal year, an increase of 3.40%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in EUR

Guerbet SA reported annual 2023 earnings of 1.75 per share on Mar 20, 2024.
Average growth rate+15.71%
More ▼

Revenue history & estimates in EUR

of 211.80m. This missed the 212.00m estimate of the one analyst following the company.
Average growth rate+3.73%
Guerbet SA had revenues for the full year 2023 of 785.70m. This was 4.30% above the prior year's results.
Average growth rate-0.71%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.